Table 2.

Differentially expressed miRNAs in CHB patients with LGDHS and LKYDS.

miRNA	Fold change (LGDHS/LKYDS)	P values
hsa-miR-494	13.66	0.0002
hsa-miR-140-3p	13.01	0.0000
hsa-miR-663	12.81	0.0028
hsa-miR-187*	11.64	0.0002
hsa-miR-936	11.43	0.0002
hsa-miR-361-5p	10.50	0.0055
hsa-miR-148a	9.49	0.0016
hsa-miR-149*	9.44	0.0018
hsa-miR-1299	8.83	0.0001
hsa-miR-708	8.81	0.0068
hsa-miR-583	8.22	0.0006
hsa-miR-760	7.47	0.0023
hsa-miR-184	7.42	0.0008
hsa-miR-30a	5.48	0.0015
hsa-miR-30e	4.88	0.0029
hsa-miR-887	4.44	0.0061
hsa-miR-345	4.07	0.0031
hsa-miR-875-5p	0.15	0.0004
hsa-miR-15b*	0.13	0.0000
hsa-miR-329	0.06	0.0011
hsa-miR-369-5p	0.03	0.0043
hsa-miR-211	0.02	0.0064

*miRNA cloning studies sometimes identify two ~22 nt sequence miRNAs which originate from the same predicted precursor. When the relative abundancies clearly indicate the predominantly expressed miRNA, the mature sequences are assigned names of the form miRNA (the predominant product) and miRNA* (from the opposite arm of the precursor). For example, miR-123 and miR-123* would share a pre-miRNA hairpin, but more miR-123 would be found in the cell. This distinction was also made with “s” (sense) and “as” (antisense) previously.